bioChip.jpg

ISRAEL GENERIC BIOCHIP TECHNOLOGY  CONSORTIUM

 

The Israeli Bio-Chip consortium has been organized and financed by the MAGNET Program of the Israel Innovation Authority. The consortium consists of 7 industrial companies (Tower SC, CEVA, PLSense QuLab medical, Cardiokol , SensoMedical, Israel Aerospace Industry) and 12 research groups from 4 different academic institutes (Technion, Bar-Ilan, Ben-Gurion, TAU).  
The main goal of the consortium is to develop and bring to market innovative-generic Bio-chips technologies which will be available for the emerging Israeli Bio-Medical sector and will bridge the current existing gap in the industry.

The consortium will develop various biosensors and supportive technologies with emphasis on innovative low power circuits, chip manufacturing technologies, microfluidics, optical applications, and AI capabilities needed for bio-chip based systems. The  technologies will be demonstrated on metabolic sensing, innovative heart-arrhythmia detection, analog bio-sensors, EEG, synthetic biology and more.  The project started in November 2021 and is planned for 3 years in 2 phases of 18 month.

 
partners.png

PARTNERS

siteLogo.png
iai-logo.png
ENG_bold.png
5ff57495c5b84b146c034544_cardiokol_logo_without_tagline.png
header_logo.png
towersemi-logo-212X89.png
new-logo_2x.png
33f9ab_498511978e2b4aa5b4055504f2709f4f.png
eng-logo.png
cs_technion-logo_2.png
799px-Bar_Ilan_logo.png
observe.png

OBSERVERS

fhg.png
Misc_HCL.png